1. Home
  2. CNTB vs ACOG Comparison

CNTB vs ACOG Comparison

Compare CNTB & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Connect Biopharma Holdings Limited

CNTB

Connect Biopharma Holdings Limited

HOLD

Current Price

$2.19

Market Cap

128.6M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$5.92

Market Cap

115.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNTB
ACOG
Founded
2012
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
128.6M
115.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CNTB
ACOG
Price
$2.19
$5.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$8.50
$18.00
AVG Volume (30 Days)
106.4K
86.7K
Earning Date
02-14-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$762,000.00
$7,427,199.00
Revenue This Year
N/A
N/A
Revenue Next Year
$24,739.01
$132.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$3.75
52 Week High
$3.28
$11.54

Technical Indicators

Market Signals
Indicator
CNTB
ACOG
Relative Strength Index (RSI) 44.39 45.47
Support Level $2.02 $6.11
Resistance Level $2.83 $6.62
Average True Range (ATR) 0.20 0.45
MACD -0.05 -0.02
Stochastic Oscillator 24.51 23.77

Price Performance

Historical Comparison
CNTB
ACOG

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: